NCT04742556View on ClinicalTrials.gov

A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

October 13, 2022

Study Completion Date

October 20, 2022

Conditions
Solid Tumors, KRAS Mutation
Interventions
DRUG

BI 3011441

BI 3011441

Trial Locations (3)

277-8577

National Cancer Center Hospital East, Chiba, Kashiwa

104-0045

National Cancer Center Hospital, Tokyo, Chuo-ku

135-8550

Japanese Foundation for Cancer Research, Tokyo, Koto-ku

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04742556 - A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive) | Biotech Hunter | Biotech Hunter